Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αvβ3
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06623-y ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Kehuang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha City, 410008, Hunan Province, China. Hauptthemen laut MEDLINE: Endopeptidases, Integrin alphaVbeta3, Membrane Proteins, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Several studies have demonstrated the advantages of heterodimers over their corresponding monomers due to the multivalency effect. This effect leads to an increased number of effective targeted receptors and, consequently, improved tumor uptake. Fibroblast activation protein (FAP) and integrin αvβ3 are found to be overexpressed in different components of the tumor microenvironment. In our pursuit of enhancing tumor uptake and retention, we designed and developed a novel peptidic heterodimer that synergistically targets both FAP and integrin αvβ3. METHODS: FAP-RGD was synthesized from FAP-2286 and c(RGDfK) through a multi-step organic synthesis. The dual receptor binding property of 68Ga-FAP-RGD was investigated by cell uptake and competitive binding assays. Preclinical pharmacokinetics were determined in HT1080-FAP and U87MG tumor models using micro-positron emission tomography/computed tomography (micro-PET/CT) and biodistribution studies. The antitumor efficacy of 177Lu-FAP-RGD was assessed in U87MG tumor models. The radiation exposure and clinical diagnostic performance of 68 Ga-FAP-RGD were evaluated in healthy volunteers and cancer patients. RESULTS: Bi-specific radiotracer 68Ga-FAP-RGD exhibited high binding affinity for both FAP and integrin αvβ3. In comparison to 68Ga-FAP-2286 and 68Ga-RGDfK, 68Ga-FAP-RGD displayed enhanced tumor uptake and longer tumor retention time in preclinical models. 177Lu-FAP-RGD could efficiently suppress the growth of U87MG tumor in vivo when applied at an activity of 18.5 and 29.6 MBq. The effective dose of 68Ga-FAP-RGD was 1.06 × 10-2 mSv/MBq. 68Ga-FAP-RGD demonstrated low background activity and stable accumulation in most neoplastic lesions up to 3 h. CONCLUSION: Taking the advantages of multivalency effect, the bi-specific radiotracer 68Ga-FAP-RGD showed superior tumor uptake and retention compared to its corresponding monomers. Preclinical studies with 68Ga- or 177Lu-labeled FAP-RGD showed favorable image contrast and effective antitumor responses. Despite the excellent performance of 68Ga-FAP-RGD in clinical diagnosis, experimental efforts are currently underway to optimize the structure of FAP-RGD to increase its potential for clinical application in endoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha City, 410008, Hunan Province, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Weifang Medical University, Weifang, China. pengfeixucsu@outlook.com.
- Department of Nuclear Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha City, 410008, Hunan Province, China. hushuo2018@163.com.
- Key Laboratory of Biological, Nanotechnology of National Health Commission, Changsha City, 410008, Hunan Province, China. hushuo2018@163.com.
- National Clinical Research Center for Geriatric Disorders (Xiangya), Changsha City, 410008, Hunan Province, China. hushuo2018@163.com.
ORCID-Profile: Shuo Hu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, K., Jiang, T., Rao, W., Chen, B., Yin, X., Xu, P., & Hu, S. (2024). Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αvβ3. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06623-y
Vancouver
Liu K, Jiang T, Rao W, Chen B, Yin X, Xu P, et al. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αvβ3. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06623-y
BibTeX
@article{Liu2024,
author = {Liu, Kehuang and Jiang, Tao and Rao, Wanqian and Chen, Bei and Yin, Xiaoqin and Xu, Pengfei and Hu, Shuo},
title = {Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αvβ3},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06623-y}
}
EUVIMED